Page 2

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-46 (Canceled)

47. (New) A compound of the Formula (I):

wherein:

X is phenyl;

Y is 2-pyridyl;

A is C₀ alkyl,

B is C₀ alkyl,

 $X \ is \ optionally \ substituted \ with 1-7 \ independent \ halogen, -CN, \ NO_2, -C_{1-6} alkyl, -C_{1-6} alkynyl, -C_{1-6} alkynyl, -OR^1, -NR^1R^2, -C(=NR^1)NR^2R^3, -N(=NR^1)NR^2R^3, -NR^1COR^2, -NR^1CO_2R^2, -NR^1SO_2R^4, -NR^1CONR^2R^3, -SR^4, -SOR^4, -SO_2R^4, -SO_2NR^1R^2, -COR^1, -CO_2R^1, -CONR^1R^2, -C(=NR^1)R^2, \ or -C(=NOR^1)R^2 \ substituents, \ wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C_{1-6} alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C_{1-6} alkyl, -O(C_{0-6} alkyl), -O(C_{3-7} cycloalkyl), -O(aryl), -N(C_{0-6} alkyl)(C_{0-6} alkyl), -N(C_{0-6} alkyl)(C_{3-7} cycloalkyl), or -N(C_{0-6} alkyl)(aryl) groups; A is -C_{0} alkyl, B is -C_{0} alkyl, \\$

Y is optionally substituted with 1-7 independent halogen, -CN, NO_2 , $-\text{C}_{1}$ -6alkyl, $-\text{C}_{1}$ -6alkynyl, $-\text{OR}_5$, $-\text{NR}_5$ R6, $-\text{C}(=\text{NR}_5)\text{NR}_6$ R7, $-\text{N}(=\text{NR}_5)\text{NR}_6$ R7, $-\text{NR}_5\text{COR}_6$, $-\text{NR}_5\text{CO}_2$ R6, $-\text{NR}_5\text{CO}_2$ R8, $-\text{NR}_5\text{CONR}_6$ R7, $-\text{SR}_8$, $-\text{SO}_2$ R8, $-\text{SO}_2$ R8, $-\text{SO}_2$ R8, $-\text{SO}_2$ R8, $-\text{SO}_2$ R8, $-\text{COR}_5$, $-\text{CO}_2$ R5, $-\text{CONR}_5$ R6, $-\text{C}(=\text{NR}_5)$ R6, or

Page 3

-C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups; W is -C₃-7cycloalkyl, -heteroC₃-7cycloalkyl, -C₀-6alkylaryl, or -C₀-6alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

 $Z is -C_3-7 cycloalkyl, -heteroC_3-7 cycloalkyl, -C_0-6 alkylaryl, or -C_0-6 alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO_2, -C_1-6 alkyl, -C_1-6 alkynyl, -OR^1, -NR^1R^2, -C(=NR^1)NR^2R^3, -N(=NR^1)NR^2R^3, -NR^1COR^2, -NR^1CO_2R^2, -NR^1SO_2R^4, -NR^1CONR^2R^3, -SR^4, -SO_2R^4, -SO_2NR^1R^2, -COR^1, -CO_2R^1, -CONR^1R^2, -C(=NR^1)R^2, or -C(=NOR^1)R^2$ substituents;

one of W and Z is optionally absent;

R¹, R², and R³ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(aryl) substituents;

 $R^4 \ is \ -C_1 - 6alkyl, \ -C_3 - 7cycloalkyl, \ heteroaryl, \ or \ aryl; \ optionally substituted with 1-5 independent halogen, \ -CN, \ -C_1 - 6alkyl, \ -O(C_0 - 6alkyl), \ -O(C_3 - 7cycloalkyl), \ -N(C_0 - 6alkyl)(C_0 - 6alkyl), \ -N(C_0 - 6alkyl)(C_3 - 7cycloalkyl), \ -N(C_0 - 6alkyl)(aryl) \ substituents;$

R⁵, R⁶, and R⁷ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

 R^8 is $-C_1$ -6alkyl, $-C_3$ -7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, $-C_1$ -6alkyl, $-O(C_0$ -6alkyl), $-O(C_3$ -7cycloalkyl), $-N(C_0$ -6alkyl)(C_0 -6alkyl)

Page 4

 R^9 and R^{10} each independently is $-C_{0\text{-}6}$ alkyl, $-C_{3\text{-}7}$ cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, $-C_{1\text{-}6}$ alkyl, $-O(C_{0\text{-}6}$ alkyl), $-O(C_{3\text{-}7}$ cycloalkyl), -O(aryl), $-N(C_{0\text{-}6}$ alkyl)($C_{0\text{-}6}$ alkyl), $-N(C_{0\text{-}6}$ alkyl)(aryl) substituents; and

any N may be an N-oxide; or a pharmaceutically acceptable salt thereof.

48. (New) The compound according to Claim 47 wherein:

 $X is phenyl, which is optionally substituted with 1-5 independent halogen, -CN, NO_2, -C_{1-6}alkyl, -C_{1-6}alkenyl, -C_{1-6}alkynyl, -OR^1, -NR^1R^2, -C(=NR^1)NR^2R^3, -N(=NR^1)NR^2R^3, -NR^1COR^2, -NR^1CO_2R^2, -NR^1SO_2R^4, -NR^1CONR^2R^3, -SR^4, -SOR^4, -SO_2R^4, -SO_2NR^1R^2, -COR^1, -CO_2R^1, -CONR^1R^2, -C(=NR^1)R^2, or -C(=NOR^1)R^2$ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C_{1-6}alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C_{1-6}alkyl, -O(C_{0-6}alkyl), -O(C_{3-7}cycloalkyl), -O(aryl), -N(C_{0-6}alkyl)(C_{0-6}alkyl), -N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), or -N(C_{0-6}alkyl)(aryl) groups.

49. (New) The compound according to Claim 47 wherein:

Y is 2-pyridyl, which is optionally substituted with 1-4 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SO₂R⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -N(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups.

50. (New) The compound according to Claim 47 wherein:

W is $-C_0$ -6alkylaryl, or $-C_0$ -6alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO_2 , $-C_1$ -6alkyl, $-C_1$ -6alkenyl, $-C_1$ -6alkynyl, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-NR^1COR^2$, $-NR^1CO_2R^2$, $-NR^1SO_2R^4$, $-NR^1CONR^2R^3$, $-SR^4$, $-SO_2R^4$, $-SO_2NR^1R^2$, $-COR^1$, $-CO_2R^1$, $-CONR^1R^2$, $-C(=NR^1)R^2$, or $-C(=NOR^1)R^2$ substituents.

Page 5

51. (New) A compound which is selected from the group consisting of:

1-methyl-3-[3-(5-pyridin-2-yl-2*H*-tetrazol-2-yl)phenyl]imidazolidin-2-one;

2-[2-(4-pyridin-2-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;

2-[2-(4-pyridin-4-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;

2-{2-[3-(1*H*-imidazol-1-yl)phenyl]-2*H*-tetrazol-5-yl}pyridine;

2-[2-(2-pyrazin-3-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;

2-[2-(4-morpholin-3-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;

2-{2-[3-(2*H*-tetrazol-5-yl)phenyl]-2*H*-tetrazol-5-yl}pyridine; and

2-pyridin-2-yl-5-(5-pyridin-2-yl-2*H*-tetrazol-2-yl)benzonitrile;

or a pharmaceutically acceptable salt thereof.

52. (New) A compound which selected from the group consisting of:

10

10/506,479 MS0007YP 15 Serial No.: Case No.: Page

10/506,479 MS0007YP 17 Serial No.: Case No.: Page

Page 26

or a pharmaceutically acceptable salt thereof.

Page 27

53. (New) A pharmaceutical composition comprising the compound of Claim 47, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

- 54. (New) A pharmaceutical composition comprising the compound of Claim 51, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 55. (New) A pharmaceutical composition comprising the compound of Claim 52, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.